NCT00419419

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (planned)
• Sponsor: MediQuest Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Detailed description

The purpose of this clinical study is to determine, in a controlled fashion, the ability of Topical AmphiMatrix formulation with Nitroglycerin (MQX-503) to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases such as scleroderma.

Conditions

• Raynaud's Disease
• Scleroderma
• Autoimmune Diseases

Interventions

Type	Name	Description
DRUG	Topical AmphiMatrix with nitroglycerin (MQX-503)

Timeline

• Start date: 2006-12-01
• First posted: 2007-01-08
• Last updated: 2007-05-30

Locations

12 sites across 3 countries: United States, Sweden, United Kingdom